247 related articles for article (PubMed ID: 20018674)
1. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.
Simonaro CM; Ge Y; Eliyahu E; He X; Jepsen KJ; Schuchman EH
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):222-7. PubMed ID: 20018674
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI.
Eliyahu E; Wolfson T; Ge Y; Jepsen KJ; Schuchman EH; Simonaro CM
PLoS One; 2011; 6(8):e22447. PubMed ID: 21887218
[TBL] [Abstract][Full Text] [Related]
3. Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII.
Rowan DJ; Tomatsu S; Grubb JH; Montaño AM; Sly WS
J Inherit Metab Dis; 2013 Mar; 36(2):235-46. PubMed ID: 22971960
[TBL] [Abstract][Full Text] [Related]
4. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses.
Schuchman EH; Ge Y; Lai A; Borisov Y; Faillace M; Eliyahu E; He X; Iatridis J; Vlassara H; Striker G; Simonaro CM
PLoS One; 2013; 8(1):e54459. PubMed ID: 23365668
[TBL] [Abstract][Full Text] [Related]
5. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice.
Jung YO; Cho ML; Lee SY; Oh HJ; Park JS; Park MK; Park MJ; Ju JH; Kim SI; Park SH; Kim HY; Min JK
Immunol Lett; 2009 Apr; 123(2):138-43. PubMed ID: 19428561
[TBL] [Abstract][Full Text] [Related]
6. Role of Toll like receptor 4 signaling pathway in the secondary damage induced by experimental spinal cord injury.
Impellizzeri D; Ahmad A; Di Paola R; Campolo M; Navarra M; Esposito E; Cuzzocrea S
Immunobiology; 2015 Sep; 220(9):1039-49. PubMed ID: 25990044
[TBL] [Abstract][Full Text] [Related]
7. [Are there any positive effects of TNF-alpha blockers on bone metabolism?].
Seriolo B; Paolino S; Sulli A; Cutolo M
Reumatismo; 2006; 58(3):199-205. PubMed ID: 17013436
[TBL] [Abstract][Full Text] [Related]
8. [β1 receptor blocker decreases the myocardial inflammation in the sepsis adult rats through inhibition of TLR4/NF-ΚB signaling pathway].
Liu X; Wen M; Li X; Chen L; Zeng J; Deng Y; Zeng H
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Feb; 31(2):193-197. PubMed ID: 30827308
[TBL] [Abstract][Full Text] [Related]
9. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components.
Dobrovolskaia MA; Medvedev AE; Thomas KE; Cuesta N; Toshchakov V; Ren T; Cody MJ; Michalek SM; Rice NR; Vogel SN
J Immunol; 2003 Jan; 170(1):508-19. PubMed ID: 12496438
[TBL] [Abstract][Full Text] [Related]
10. Impact of miR-223-3p and miR-2909 on inflammatory factors IL-6, IL-1ß, and TNF-α, and the TLR4/TLR2/NF-κB/STAT3 signaling pathway induced by lipopolysaccharide in human adipose stem cells.
Wu J; Niu P; Zhao Y; Cheng Y; Chen W; Lin L; Lu J; Cheng X; Xu Z
PLoS One; 2019; 14(2):e0212063. PubMed ID: 30807577
[TBL] [Abstract][Full Text] [Related]
11. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
12. Hyperoside exerts anti-inflammatory and anti-arthritic effects in LPS-stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis.
Jin XN; Yan EZ; Wang HM; Sui HJ; Liu Z; Gao W; Jin Y
Acta Pharmacol Sin; 2016 May; 37(5):674-86. PubMed ID: 27041460
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.
Shanahan JC; St Clair W
Clin Immunol; 2002 Jun; 103(3 Pt 1):231-42. PubMed ID: 12173297
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody against Toll-like receptor 4 attenuates ventilator-induced lung injury in rats by inhibiting MyD88- and NF-κB-dependent signaling.
Huang C; Pan L; Lin F; Dai H; Fu R
Int J Mol Med; 2017 Mar; 39(3):693-700. PubMed ID: 28204830
[TBL] [Abstract][Full Text] [Related]
15. Sodium Butyrate Inhibits the Inflammation of Lipopolysaccharide-Induced Acute Lung Injury in Mice by Regulating the Toll-Like Receptor 4/Nuclear Factor κB Signaling Pathway.
Liu J; Chang G; Huang J; Wang Y; Ma N; Roy AC; Shen X
J Agric Food Chem; 2019 Feb; 67(6):1674-1682. PubMed ID: 30661349
[TBL] [Abstract][Full Text] [Related]
16. Lipopolysaccharide inhibits myogenic differentiation of C2C12 myoblasts through the Toll-like receptor 4-nuclear factor-κB signaling pathway and myoblast-derived tumor necrosis factor-α.
Ono Y; Sakamoto K
PLoS One; 2017; 12(7):e0182040. PubMed ID: 28742154
[TBL] [Abstract][Full Text] [Related]
17. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis.
Paleolog E
Expert Opin Investig Drugs; 2003 Jul; 12(7):1087-95. PubMed ID: 12831345
[TBL] [Abstract][Full Text] [Related]
19. Plasma membrane-bound G protein-coupled bile acid receptor attenuates liver ischemia/reperfusion injury via the inhibition of toll-like receptor 4 signaling in mice.
Yang H; Zhou H; Zhuang L; Auwerx J; Schoonjans K; Wang X; Feng C; Lu L
Liver Transpl; 2017 Jan; 23(1):63-74. PubMed ID: 27597295
[TBL] [Abstract][Full Text] [Related]
20. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
